0001737287
2025-01-01
2025-12-31
0001737287
2024-01-01
2024-12-31
0001737287
2023-01-01
2023-12-31
0001737287
ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember
ecd:PeoMember
2025-01-01
2025-12-31
0001737287
ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember
ecd:PeoMember
2025-01-01
2025-12-31
0001737287
ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
ecd:PeoMember
2025-01-01
2025-12-31
0001737287
ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
ecd:PeoMember
2025-01-01
2025-12-31
0001737287
ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember
ecd:PeoMember
2025-01-01
2025-12-31
0001737287
ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember
ecd:NonPeoNeoMember
2025-01-01
2025-12-31
0001737287
ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember
ecd:NonPeoNeoMember
2025-01-01
2025-12-31
0001737287
ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
ecd:NonPeoNeoMember
2025-01-01
2025-12-31
0001737287
ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
ecd:NonPeoNeoMember
2025-01-01
2025-12-31
0001737287
ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember
ecd:NonPeoNeoMember
2025-01-01
2025-12-31
0001737287
allo:ChangMember
2025-12-31
0001737287
allo:RobertsMember
2025-12-31
0001737287
allo:ParkerMember
2025-12-31
iso4217:USD
shares
iso4217:USD
shares
pure
0001737287
DEF 14A
false
ALLOGENE THERAPEUTICS, INC.
true
<div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.611%"><tr><td style="width:1.0%"></td><td style="width:14.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-left:0.75pt solid #616365;border-right:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.75pt;padding-left:12.39pt;padding-right:12.39pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pay Versus Performance</span></div></td></tr><tr style="height:44pt"><td colspan="3" rowspan="2" style="border-left:0.75pt solid #616365;border-right:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" rowspan="2" style="border-left:0.75pt solid #616365;border-right:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.01pt;padding-right:0.01pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Summary Compensation Table Total for Principal Executive Officer (PEO)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div><div style="margin-bottom:1.5pt;padding-left:0.01pt;padding-right:0.01pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" rowspan="2" style="border-left:0.75pt solid #616365;border-right:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Compensation Actually Paid to PEO</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" rowspan="2" style="border-left:0.75pt solid #616365;border-right:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.01pt;padding-right:0.01pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Average Summary Compensation Table Total for Non-PEO Named Executive Officers (NEOs)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div><div style="margin-bottom:1.5pt;padding-left:0.01pt;padding-right:0.01pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" rowspan="2" style="border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Average Compensation Actually Paid to Non-PEO NEOs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" style="border-left:0.75pt solid #616365;border-right:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value of Initial Fixed $100 Investment Based On: </span></td><td colspan="3" rowspan="2" style="border-right:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net Income (Loss)</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(thousands)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td></tr><tr style="height:44pt"><td colspan="3" style="border-left:0.75pt solid #616365;border-right:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total Shareholder Return (TSR)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($)</span></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(f)</span></td><td colspan="3" style="border-left:0.75pt solid #616365;border-right:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(g)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,136,093</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930,401</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303,234</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850,624</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.78</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #616365;border-right:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190,886)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,482,208</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872,365</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975,139</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633,611</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.86</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #616365;border-right:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257,590)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.75pt solid #616365;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.75pt solid #616365;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,063,848</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.75pt solid #616365;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291,577</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.75pt solid #616365;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,968,886</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.75pt solid #616365;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718,460</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.75pt solid #616365;border-left:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.03</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.75pt solid #616365;border-left:0.75pt solid #616365;border-right:0.75pt solid #616365;border-top:0.75pt solid #616365;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327,265)</span></td></tr></table></div>
6136093
1930401
2303234
850624
21.78
-190886000
4482208
872365
1975139
633611
33.86
-257590000
14063848
1291577
6968886
2718460
51.03
-327265000
The dollar amounts reported in column (b) are the amounts of total compensation reported for Dr. Chang (our Chief Executive Officer) for each corresponding year in the “Total” column of the Summary Compensation Table. Refer to “2025 Summary Compensation Table.”The dollar amounts reported in column (d) represent the average of the amounts reported for our Company’s NEOs as a group (excluding Dr. Chang) in the “Total” column of the Summary Compensation Table in each applicable year. The names of each of the NEOs (excluding Dr. Chang) included for purposes of calculating the average amounts in each applicable year are as follows: for 2025, Dr. Roberts and Mr. Parker, and for 2024 and 2023, Dr. Roberts and Mr. Timothy Moore, our former Executive Vice President, Chief Technical Officer.
Dr. Chang
The dollar amounts reported in column (c) represent the amount of “compensation actually paid” to Dr. Chang, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Dr. Chang during the applicable year. In accordance with Item 402(v) of Regulation S-K, the following adjustments were made to Dr. Chang’s total compensation for each year to determine the compensation actually paid:<div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.777%"><tr><td style="width:1.0%"></td><td style="width:6.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reported Summary Compensation Table Total for PEO</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deduct: Reported Value of Equity Awards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Add: Equity Award Adjustments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation Actually Paid to PEO</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,136,093</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,997,865</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792,173</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930,401</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a) The grant date fair value of equity awards represents the total of the amounts reported in the “Option Awards” and “Stock Awards” columns in the Summary Compensation Table for the applicable year.</span></div><div style="margin-bottom:3pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b) The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards that are granted and vest in the same applicable year, the fair value as of the vesting date; (iv) for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v) for awards granted in prior years that are determined to fail to meet the applicable vesting conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi) the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable year. The valuations were performed using the Black-Scholes option pricing model, the lattice option pricing model or Monte Carlo simulation. The valuation assumptions used to calculate fair values did not materially differ from those </span></div><div style="margin-bottom:3pt;padding-left:58.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.444%"><tr><td style="width:1.0%"></td><td style="width:9.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year End Fair Value of Outstanding and Unvested Equity Awards Granted in the Year</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years as of the End of the Year</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Equity Award Adjustments</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,340,632</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(872,037)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(676,421)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792,173</span></td></tr></table></div>
6136093
-4997865
792173
1930401
2340632
-872037
-676421
792173
The dollar amounts reported in column (e) represent the average amount of “compensation actually paid” to the NEOs as a group (excluding Dr. Chang), as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the NEOs as a group (excluding Dr. Chang) during 2025. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to average total compensation for the NEOs as a group (excluding Dr. Chang) for 2025 to determine the compensation actually paid, using the same methodology described above in Note (2):<div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.777%"><tr><td style="width:1.0%"></td><td style="width:6.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average Reported Summary Compensation Table Total for Non-PEO NEOs</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deduct: Average Reported Value of Equity Awards</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Add: Average Equity Award Adjustments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average Compensation Actually Paid to Non-PEO NEOs</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303,234</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574,354</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,744</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850,624</span></td></tr></table></div><div style="padding-left:40.5pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a) The amounts deducted or added in calculating the total average equity award adjustments are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.444%"><tr><td style="width:1.0%"></td><td style="width:9.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average Year End Fair Value of Outstanding and Unvested Equity Awards Granted in the Year</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years as of the End of the Year</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Average Equity Award Adjustments</span></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737,207</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(397,194)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218,269)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,744</span></td></tr></table></div>
2303234
-1574354
121744
850624
737207
-397194
-218269
121744
Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our Company’s share price at the end and the beginning of the measurement period by our Company’s share price at the beginning of the measurement period. No dividends were paid on stock or option awards in 2023, 2024 or 2025.The dollar amounts reported represent the amount of net income (loss) reflected in our consolidated audited financial statements for the applicable year.<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#05686f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Analysis of the Information Presented in the Pay Versus Performance Table</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We generally seek to incentivize long-term performance, and therefore do not specifically align our performance measures with “compensation actually paid” (as computed in accordance with Item 402(v) of Regulation S-K) for a particular year. In accordance with Item 402(v) of Regulation S-K, we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance table.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company is a pre-commercial biotechnology company and, as such, does not currently use revenue, profitability, or other traditional financial performance measures as primary drivers of executive compensation. Instead, the Company’s executive compensation program emphasizes long-term value creation through equity-based incentives and the achievement of key strategic and clinical development milestones, which the Compensation Committee believes are the most meaningful indicators of performance at this stage of the Company’s lifecycle.</span></div>
<div style="margin-bottom:6pt;margin-top:12pt;text-indent:27.35pt"><span style="color:#05686f;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Compensation Actually Paid and Net Income (Loss)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Because we are a clinical-stage company, we did not have any product-based revenue during the periods presented. Consequently, we have not historically looked to net income (loss) as a performance measure for our executive compensation program. We also expect and have experienced higher net losses over time as we progress the development of our product candidates through clinical trials. Moreover, as a pre-commercial stage company with only limited, nonrecurring revenue associated with collaborations, we do not believe there is any meaningful relationship between our net loss and compensation actually paid to our NEOs during the periods presented.</span></div><div style="margin-top:6pt;text-align:center"><img alt="Paid and NL.jpg" id="i-17" src="allo-20260430_g16.jpg" style="height:317px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div>
<div style="margin-bottom:6pt;margin-top:12pt;text-indent:27.35pt"><span style="color:#05686f;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Compensation Actually Paid and Cumulative TSR</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The chart below shows the relationship between compensation actually paid to our PEO, the average of compensation actually paid to our non-PEO NEOs, and the Company’s cumulative TSR over the three most recently completed fiscal years.</span></div><div style="margin-top:6pt;text-align:center"><img alt="Paid and TSR.jpg" id="i-18" src="allo-20260430_g17.jpg" style="height:316px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">All information provided above under the “Pay Versus Performance” heading will not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such information by reference.</span></div>
<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">From time to time, the Company grants stock options to its employees, including its named executive officers. Historically, the Company has typically granted new-hire option awards on or soon after a new hire’s employment start date and promotion option awards on or soon after the employee’s promotion date. Annual refresh employee option grants are typically granted at a regularly scheduled Compensation Committee meeting toward the end of January of each year. The grant date for these annual refresh grants is typically approximately the first trading day following the date of approval, </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">although in the past that timing has deviated for logistical reasons. The Company maintains a written grant policy for its Non-Officer Stock Award Committee ("NOSAC") for grants to employees who are not Section 16 officers and who hold a title below Senior Vice President. This policy provides that option grants shall generally be on the first or fifteenth day of the month (or if such date is not a market trading day, then on the next subsequent trading day), whichever date coincides with or follows the approval of the grant by the NOSAC. Also, non-employee directors receive automatic grants of initial and annual stock option awards, at the time of a director’s initial appointment or election to the Board and at the time of each annual meeting of the Company’s stockholders, respectively, pursuant to the Non-Employee Director Compensation Policy, as further described below under the heading, “Non-Employee Director Compensation Policy.” The Company does not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features. Because the Compensation Committee has a practice of generally granting stock options for new hires, promotions and refresh grants at specified times as described above, the Compensation Committee generally does not take material nonpublic information ("MNPI") into account when determining the timing or terms of stock option awards and does not seek to time the award of stock options in relation to the Company’s public disclosure of MNPI. The Company has not timed the release of MNPI for the purpose of affecting the value of executive compensation.</span></div>
Historically, the Company has typically granted new-hire option awards on or soon after a new hire’s employment start date and promotion option awards on or soon after the employee’s promotion date. Annual refresh employee option grants are typically granted at a regularly scheduled Compensation Committee meeting toward the end of January of each year. The grant date for these annual refresh grants is typically approximately the first trading day following the date of approval, although in the past that timing has deviated for logistical reasons. The Company maintains a written grant policy for its Non-Officer Stock Award Committee ("NOSAC") for grants to employees who are not Section 16 officers and who hold a title below Senior Vice President. This policy provides that option grants shall generally be on the first or fifteenth day of the month (or if such date is not a market trading day, then on the next subsequent trading day), whichever date coincides with or follows the approval of the grant by the NOSAC. Also, non-employee directors receive automatic grants of initial and annual stock option awards, at the time of a director’s initial appointment or election to the Board and at the time of each annual meeting of the Company’s stockholders, respectively, pursuant to the Non-Employee Director Compensation Policy, as further described below under the heading, “Non-Employee Director Compensation Policy.” The Company does not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features.
true
Because the Compensation Committee has a practice of generally granting stock options for new hires, promotions and refresh grants at specified times as described above, the Compensation Committee generally does not take material nonpublic information ("MNPI") into account when determining the timing or terms of stock option awards and does not seek to time the award of stock options in relation to the Company’s public disclosure of MNPI.
false
false
<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.694%"><tr><td style="width:1.0%"></td><td style="width:27.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.48pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.48pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant date</span></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.48pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of securities underlying the award</span></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.48pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise price of the award ($/Sh)</span></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.48pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant date fair value of the award</span></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.97pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Chang, M.D., Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.97pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/24/2025</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952,130</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.94</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,588,329</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-4.66%</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.97pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zachary Roberts, M.D., Ph.D.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.97pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/24/2025</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614,844</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.94</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$815,222</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-4.66%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.97pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geoffrey Parker</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.97pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/24/2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614,844</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.94</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$815,222</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1.97pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-4.66%</span></td></tr></table></div>
David Chang, M.D., Ph.D.
1952130
1.94
2588329
-0.0466
Zachary Roberts, M.D., Ph.D.
614844
1.94
815222
-0.0466
Geoffrey Parker
614844
1.94
815222
-0.0466